Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | TPMT | P51580 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307376 | 1.00 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL14903561 | 0.89 | TSHR (0.67) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL12963322 | 0.87 | TSHR (0.68) | TSHRABCG2MAPTLMNAMEN1 | |
| SCHEMBL19632973 | 0.86 | ABCG2 (0.47) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL3751049 | 0.86 | SLC22A6 (0.66) | CYP1A2ABCG2MEN1KMT2A | |
| SCHEMBL28643734 | 0.86 | TUBB1 (0.55) | ABCG2MEN1KMT2AALDH1A1 | |
| SCHEMBL1824154 | 0.84 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL4895137 | 0.84 | ALDH1A1 (0.49) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL20007220 | 0.84 | ABCG2 (0.49) | CYP1A2CYP3A4CYP2C19ABCG2MAPT | |
| SCHEMBL20007006 | 0.84 | HTT (0.65) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875285-B1 | n acrylic ester polymer including a drug having anovercoating of a different acrylic ester polymer having a glass transition temperature of 35-50 degrees C. to control elution of the drug; temperature change morphology of drug polymer to change and increase release; thrombolytic agents; restenosis | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2011-01-25 | — | — | US | claimed |
| CN-1376660-A | Synthesis of substituted trans-cinnamic aldehyde-natural yellow dyestuff from phenylpropyl alkyl derivatives | COUNCIL SCIENT IND RES (IN) | 2002-10-30 | — | — | CN | claimed |
| CN-120005686-A | Composition comprising lipase and sulfite | 诺维信公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-110651038-B | Composition comprising lipase and sulfite | 诺维信公司 | 2025-02-18 | — | — | CN | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| CN-1500769-A | Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | ���µ�˹ҩ�﹫˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1496999-A | Solid phase synthesing method of aldehyde, ketonic, oxime amine and isohydroximic acid compound | ���µ�˹ҩ�﹫˾ | 2004-05-19 | — | — | CN | disclosed |
| CN-1132807-C | Solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | RHONE POULENC RORER PHARMA (US) | 2003-12-31 | — | — | CN | disclosed |
| CN-1429202-A | Compounds for modulating cell proliferation | HSC RES & DEV LTD PARTNERSHIP (CA) | 2003-07-09 | — | — | CN | disclosed |
| CN-1376660-A | Synthesis of substituted trans-cinnamic aldehyde-natural yellow dyestuff from phenylpropyl alkyl derivatives | COUNCIL SCIENT IND RES (IN) | 2002-10-30 | — | — | CN | disclosed |
| CN-1307553-A | Solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVANTIES MEDICINE PRODUCT CO (US) | 2001-08-08 | — | — | CN | disclosed |
| CN-1296493-A | Aspartyl dipeptide ester derivatives and sweeteners | AJINOMOTO KK (JP) | 2001-05-23 | — | — | CN | disclosed |
| CN-1240418-A | Solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | RHONE POULENC RORER PHARMA (US) | 2000-01-05 | — | — | CN | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | CYP1A2 4522/4885CYP3A4 4459/4885CYP2C9 4830/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CYP1A2 4522/4885CYP3A4 4459/4885CYP2C9 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.